Topical cyclosporin A in the management of postkeratoplasty glaucoma

Cornea. 1997 May;16(3):284-8.

Abstract

Purpose: To evaluate the effect of substituting topical cyclosporin A 0.5% for topical corticosteroids in patients with postkeratoplasty glaucoma.

Methods: Topical cyclosporin A 0.5% was prospectively substituted for topical corticosteroids to treat 25 patients with postkeratoplasty glaucoma.

Results: Twenty-one (84%) of 25 patients showed a reduction in intraocular pressure (IOP) (range, 1-22 mm Hg; mean, 8.7 mm Hg). Follow-up ranged from 3 to 12 months (mean, 5.8). Graft clarity was maintained in all patients, with one allograft rejection episode. Thirteen patients were able to discontinue one or more glaucoma medication(s).

Conclusion: Topical cyclosporin A 0.5% may be substituted for topical corticosteroids to aid in the management of postkeratoplasty patients with glaucoma. However, the resultant decrease in IOP may be associated with an increased risk for immune rejections.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Topical
  • Adult
  • Aged
  • Aged, 80 and over
  • Cyclosporine / administration & dosage
  • Cyclosporine / therapeutic use*
  • Dose-Response Relationship, Drug
  • Female
  • Follow-Up Studies
  • Glaucoma / drug therapy*
  • Glaucoma / etiology
  • Glucocorticoids / administration & dosage
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / therapeutic use*
  • Intraocular Pressure / drug effects
  • Keratoplasty, Penetrating / adverse effects*
  • Male
  • Middle Aged
  • Ophthalmic Solutions
  • Postoperative Complications / drug therapy*
  • Postoperative Complications / etiology
  • Risk Factors
  • Treatment Outcome

Substances

  • Glucocorticoids
  • Immunosuppressive Agents
  • Ophthalmic Solutions
  • Cyclosporine